MULTICENTER AIDS COHORT STUDY

多中心艾滋病队列研究

• 批准号: 7067633
• 负责人: CHARLES R RINALDO
• 金额: $ 340.17万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-05-03 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7067633
• 关键词: AIDS; AIDS dementia complex; AIDS related neoplasm /cancer; AIDS therapy; African American; HIV infections; antiAIDS agent; cardiovascular disorder; clinical research; communicable disease transmission; cooperative study; electrocardiography; epidemiology; flow cytometry; homosexuals; human immunodeficiency virus; human subject; human therapy evaluation; longitudinal human study; male; pathologic process; serology /serodiagnosis; sex behavior; tissue resource /registry; virus load

DESCRIPTION (provided by applicant): This application is Part B of a proposal for a competing renewal of the Pittsburgh component of the Multicenter AIDS Cohort Study (MACS) Cooperative Agreement (1UO1-AI-35041), the companion to the Part A composite proposal that is being submitted by CAMACS. This request is for an additional five years of support for clinical follow-up and laboratory testing of the original and recently recruited cohort of MSM in the Pittsburgh MACS. The current priority of the MACS is to enhance our epidemiologic and pathogenesis information in relation to treatment intervention. We need to describe the long-term patterns of therapy use that are consequential in terms of treatment efficacy. Our specific aims emphasize cohort retention and maintenance, biological specimen procurement and central lipid/insulin/glucose testing for dyslipidemia, diabetes, lipodystrophy and cardiovascular disease for the MACS. These are: (1) To characterize the evolving natural history of treated HIV infection and identify the determinants and trends of long-term HIV-related outcomes in the era of HAART. We will determine the effect of anti-retroviral therapies on disease incidence, surrogate markers and survival expectation. This includes special emphasis on our recently expanded cohort of young, African-American MSM, who were underrepresented in the original MACS cohort, yet maintain an inordinately greater prevalence of HIV infection in the USA. (2) To maintain the longitudinally collected epidemiological data and biological specimen repository framework of the Pittsburgh MACS as a platform to facilitate natural history and pathogenesis studies. (3) To perform the required clinical and laboratory testing of HIV seropositive and seronegative MSM in the Pittsburgh MACS. (4) To perform cardiovascular testing (Electron Beam Computed Tomography [EBCT], carotid intima media thickness [IMT], and EKG testing) on a sub-sample of the MACS to address key questions related to risk of cardiovascular disease among HAART recipients. We believe that through these aims, as well as through substudies on the immunopathogenesis of HIV infection that are closely linked to the Pittsburgh MACS, we will significantly contribute to the scientific agenda and goals of the MACS.

描述（由申请人提供）： 本申请是多中心艾滋病队列研究 (MACS) 合作协议 (1UO1-AI-35041) 匹兹堡部分竞争更新提案的 B 部分，该提案是 CAMACS 提交的 A 部分综合提案的姊妹篇。 该请求是为匹兹堡 MACS 最初和最近招募的 MSM 队列提供额外五年的临床随访和实验室测试支持。 MACS 当前的首要任务是增强与治疗干预相关的流行病学和发病机制信息。我们需要描述对治疗效果有重要影响的长期治疗使用模式。我们的具体目标强调 MACS 的队列保留和维护、生物样本采购以及血脂异常、糖尿病、脂肪营养不良和心血管疾病的中心脂质/胰岛素/葡萄糖检测。这些是： (1) 描述治疗后 HIV 感染的自然史演变，并确定 HAART 时代长期 HIV 相关结果的决定因素和趋势。 我们将确定抗逆转录病毒疗法对疾病发生率、替代标志物和生存率的影响 期待。这包括特别强调我们最近扩大的年轻非裔美国男男性接触者群体，他们在最初的 MACS 群体中代表性不足，但在美国艾滋病毒感染率仍然异常高。 （2）维护匹兹堡MACS纵向收集的流行病学数据和生物标本存储库框架，作为促进自然史和发病机制研究的平台。 (3) 在匹兹堡 MACS 中对 HIV 血清阳性和血清阴性 MSM 进行所需的临床和实验室检测。 (4) 对 MACS 的子样本进行心血管检测（电子束计算机断层扫描 [EBCT]、颈动脉内膜中层厚度 [IMT] 和心电图检测），以解决与 HAART 接受者心血管疾病风险相关的关键问题。 我们相信，通过这些目标，以及通过与匹兹堡 MACS 密切相关的 HIV 感染免疫发病机制的子研究，我们将为 MACS 的科学议程和目标做出重大贡献。